Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Rainey fourth quarter and full year 2025 financial results and corporate update conference call. At this time, all participants are on a listen-only mode. Following managers' prepared remarks, Rainey will hold a QA session. To ensure that you have ample time to address everyone's questions during the QA session, we will ask you to limit yourself to one question and one follow-up. To ask a question at that time, please press star 11 on your touchtone telephone. As a reminder, this call is being recorded today, March 26th, 2026. I would now like to turn the conference over to your speaker for today. Steven Jasper of Gilmartin Group, please go ahead. Thank you, Operator. Joining us on the call today from Ronnie Therapeutics are Chief Executive Officer Talat Imran and Chief Financial Officer Svye Sanford. Earlier today, Ronnie released financial results for the quarter and year-ended December 31st, 2025. A copy of the press release is available on the company's website. During this conference call, management will make forward-looking statements that are subject to risks, uncertainties, and assumptions, such as, but not limited to those discussed in the risk factors section of the company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed today. which identified the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These statements may include, without limitation, statements regarding product development and clinical trials, product potential, market sizes, platform progress, platform potential, certain business strategies, strategic partnership with Chugai, including potential milestone payments under the Chugai license ...